CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Blueprint
Medicines Corporation (Nasdaq: BPMC) today announced its
participation in the following upcoming investor
conferences:
- 22nd Annual Needham Healthcare Conference, held
virtually, on Tuesday, April 18, 2023
at 2:15 p.m. ET.
- Stifel 2023 Targeted Oncology Days, held virtually, on
Tuesday, April 25, 2023 at
11:30 a.m. ET.
A live webcast of each presentation will be available by
visiting the "Events and Presentations" section of Blueprint
Medicines' website at http://ir.blueprintmedicines.com. A replay of
the webcasts will be archived on Blueprint Medicines' website for
30 days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate science into a broad pipeline of
precision therapies. Today, we are delivering our approved
medicines to patients in the United
States and Europe, and we
are globally advancing multiple programs for systemic mastocytosis,
lung cancer, breast cancer and other genomically defined cancers,
and cancer immunotherapy. For more information, visit
www.BlueprintMedicines.com and follow us on Twitter
(@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-301793758.html
SOURCE Blueprint Medicines Corporation